Curcumin Enhances the Anti-Cancer Efficacy of CDK4/6 Inhibitors in Prostate Cancer

• DOI: 10.56434/j.arch.esp.urol.20247701.8
• Publication Date: 2024-02-01T09:15:31Z
• Authors: Huandong Zhao; Ruimin Ding; Jiarui Han
• Keywords: Viability assay; Cyclin-dependent kinase 6

Objective: This study aimed to investigate the potential of combining cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with curcumin (Cur), a natural compound known for its anti-aging properties, enhance anti-cancer efficacy in prostate cancer (PCa). Methods: The cell viability was determined by counting kit-8 assay, colony forming assay invasion. cycle mRNA levels p16 (cyclin dependent inhibitor 2A, CDKN2A), p21 1A, CDKN1A) <i>Rb</i> (RB transcriptional corepressor) were detected flow cytometry quantitative real-time polymerase chain reaction, respectively. SA-β-gal staining interleukin (IL6) used evaluate aging. Western blot detect mechanistic targets rapamycin (mTOR) signal transducer activator transcription 3 (STAT3) pathways. Moreover, Sphere formation aldehyde dehydrogenase (ALDH) 1A1, CD44 Nanog determine stemness. Results: combination LY2835219 (LY, CDK4/6 inhibitor) Cur exhibited synergistic inhibitory effect on PCa proliferation (<i>p</i> < 0.01) invasion gene expression 0.05), as well promotive p61 0.01), G1 arrest cells 0.05) compared LY or alone. + increased SA-β-gal-stained 0.01). mTOR STAT3 pathway decreased Furthermore, conditioned medium (CM) inhibited stemness decreasing spheres ALDH1A1 CM. Conclusions: findings this suggested that may have clinical implications treatment PCa.